Ovarian Cancer

IMV Inc (NASDAQ: IMV) has announced the final topline results of the DeCidE1 Phase 2 trial evaluating maveropepimut-S (MVP-S, formerly known as DPX-Survivac) for advanced, recurrent ovarian cancer. The results showed that treatment was well-tolerated, with an overall survival rate...

Sellas Life Sciences Group Inc (NASDAQ: SLS) has announced updated data and initial immunobiological data from its Phase 1/2 evaluating its lead asset, galinpepimut-S (GPS), in ovarian cancer. Conducted in collaboration with Merck & Co Inc (NYSE: MRK), the study is...

The FDA notified VBL Therapeutics Ltd (NASDAQ: VBLT) that clearance of new VB-111 batches for use in the U.S. is currently pending, as review by the Chemistry, Manufacturing, and Controls (CMC) group is still ongoing. VB-111 (ofranergene obadenovec) gene therapy for ovarian cancer. Until...

VBL Therapeutics Ltd (NASDAQ: VBLT) has amended the primary endpoint in the OVAL Phase 3 registration-enabling study of VB-111 (ofranergene obadenovec) gene therapy for ovarian cancer. Following discussion with the FDA, the clinical trial amendment includes a second,...

The FDA has granted Breakthrough Therapy designation to Verastem Inc (NASDAQ: VSTM) for the combination of its investigational VS-6766, with defactinib, for recurrent low-grade serous ovarian cancer (LGSOC) regardless of KRAS status after one or more prior lines of therapy...

Cancer Focus Fund LP, established in collaboration with The University of Texas MD Anderson Cancer Center and Mereo BioPharma Group plc (NASDAQ: MREO), has entered into a funding agreement. The partnership will support a Phase 1b/2 clinical study of etigilimab combined with an...

Mersana Therapeutics Inc (NASDAQ: MRSN) has initiated patient dosing in the UPLIFT study evaluating upifitamab rilsodotin in patients with ovarian cancer. The single-arm registration strategy will evaluate the safety and efficacy of upifitamab rilsodotin in platinum-resistant...

Celsion Corporation (NASDAQ: CLSN) has announced a poster highlighting its ongoing Phase 1/2 OVATION 2 Study with GEN-1 in advanced ovarian cancer was presented last week at the Virtual Annual Meeting on Women’s Cancer. GEN-1 is a DNA-mediated interleukin-12 (IL-12)...

A jury in California ordered Johnson & Johnson (NYSE: JNJ) to pay $417 million to a woman who claimed the company’s talcum powder gave her cancer, the latest in a recent string of successful lawsuits. Eva Echeverria, 63, said she started using baby powder when she was 11 years old. She...

Analysts at Leerink maintain an Outperform rating on shares ofClovis Oncology Inc (NASDAQ: CLVS) with a price target boosted from $85 to $114 after the company hosted a conference call on Monday, which addressed some of the biggest controversies it faces. Clovis' conference calls came after the...